XML 61 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Summary of Reportable Segment Information
The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
Twelve Months Ended December 31,
202420232022
Total revenues$2,853,915 $2,419,226 $2,096,039 
Less:
Cost of sales580,235 532,062 503,023 
R&D expenses
Research and early pipeline434,023 393,078 313,915 
Later-stage clinical programs27,581 62,604 119,015 
Marketed products285,580 291,091 216,676 
SG&A expenses
S&M expenses
476,739 488,442 450,349 
G&A expenses
532,286 403,964 372,894 
Other segment expense (income), net (1)
90,612 80,340 (21,394)
Net income$426,859 $167,645 $141,561 
(1)Other segment expense (income), net during the years ended December 31, 2024, 2023 and 2022 include Intangible asset amortization, Interest income and expense, Other expense, net and the Provision for income taxes. The years ended December 31, 2024 and 2022 also include Gain on sale of nonfinancial assets.
Schedule of Total Revenues and Disaggregates Net Product Revenues by Product
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Years Ended December 31,
202420232022
VIMIZIM$739,784 $701,053 $663,739 
VOXZOGO735,092 469,881 169,128 
NAGLAZYME479,584 420,292 443,794 
PALYNZIQ355,047 303,919 255,032 
ALDURAZYME183,887 131,248 128,422 
BRINEURA169,083 161,889 154,333 
KUVAN120,902 180,767 227,577 
ROCTAVIAN26,066 3,489 — 
Total net product revenues2,809,445 2,372,538 2,042,025 
Royalty and other revenues44,470 46,688 54,014 
Total revenues$2,853,915 $2,419,226 $2,096,039 
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
Years Ended December 31,
202420232022
United States$924,810 $771,314 $684,284 
Europe829,031 669,331 650,952 
Latin America378,084 332,437 266,801 
Rest of world493,633 468,208 311,566 
Total net product revenues marketed by the Company2,625,558 2,241,290 1,913,603 
ALDURAZYME net product revenues marketed by Sanofi183,887 131,248 128,422 
Total net product revenues$2,809,445 $2,372,538 $2,042,025 
Schedule of Total Net Product Revenues Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Years Ended December 31,
202420232022
Customer A13 %14 %16 %
Customer B12 %12 %12 %
Total25 %26 %28 %
Schedule of Long-Lived Assets by Geographic Region
Long-lived assets, which consist of net property, plant and equipment and ROU assets are summarized by geographic region in the following table.
December 31,
20242023
Long-lived assets by geography:
United States$755,069 $788,590 
Ireland308,123 306,542 
Rest of world13,600 17,075 
Total long-lived assets$1,076,792 $1,112,207